Breakthrough Therapy Designation for Atopic Dermatitis
AbbVie’s Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis. Atopic dermatitis, a chronic inflammatory skin disease, is characterized by skin erosion, oozing and crusting, redness, intense itching (pruritus) and dry skin.12 Symptoms can appear as a rash on the skin, or the skin may become thickened and leathery.
